Generic Drug 180-Day Exclusivity Reform Proposal Is Cost-Neutral, CBO Says

Sen. Orrin Hatch (R-Utah) is likely to continue to push for changes in the 180-day generic drug exclusivity provisions in Medicare legislation despite a cost-neutral CBO score on the approach already included in the Senate legislation